
Spyre Therapeutics Inc
NASDAQ:SYRE

Intrinsic Value
The intrinsic value of one
SYRE
stock under the Base Case scenario is
9.99
USD.
Compared to the current market price of 15.76 USD,
Spyre Therapeutics Inc
is
Overvalued by 37%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Spyre Therapeutics Inc
Loading...
Fundamental Analysis


Revenue & Expenses Breakdown
Spyre Therapeutics Inc
Balance Sheet Decomposition
Spyre Therapeutics Inc
Current Assets | 608.5m |
Cash & Short-Term Investments | 603.1m |
Other Current Assets | 5.4m |
Non-Current Assets | 10k |
Other Non-Current Assets | 10k |
Free Cash Flow Analysis
Spyre Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Spyre Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-208.6m
USD
|
Operating Income
|
-208.6m
USD
|
Other Expenses
|
548k
USD
|
Net Income
|
-208m
USD
|
SYRE Profitability Score
Profitability Due Diligence
Spyre Therapeutics Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

Score
Spyre Therapeutics Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
SYRE Solvency Score
Solvency Due Diligence
Spyre Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Score
Spyre Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SYRE Price Targets Summary
Spyre Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
SYRE
is 55.42 USD
with a low forecast of 21.21 USD and a high forecast of 74.55 USD.
Dividends
Current shareholder yield for SYRE is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
SYRE
stock under the Base Case scenario is
9.99
USD.
Compared to the current market price of 15.76 USD,
Spyre Therapeutics Inc
is
Overvalued by 37%.